ALB and Hypertension: As listed in Table 6, the most common AEs of lenvatinib were decreased albumin (n = 28, 54.9%), hypertension (n = 23, 45.1%), increased AST (n = 21, 41.2%), and increased TB (n = 18, 35.2%).